C4 Therapeutics Inc
(NAS:CCCC)
$
4.06
-0.24 (-5.58%)
Market Cap: 286.59 Mil
Enterprise Value: 114.99 Mil
PE Ratio: 0
PB Ratio: 1.25
GF Score: 60/100 C4 Therapeutics Inc at Stifel Targeted Oncology Days (Virtual) Transcript
Apr 26, 2023 / 03:00PM GMT
Release Date Price:
$3.05
Brad Canino
Stifel Financial Corp. - Analyst
Great. Thanks, everyone, for continuing to join us on our second day of the inaugural Stifel Targeted Oncology Days. My name is Brad Canino, senior analyst here at Stifel. I'm happy to continue the fireside chat session with C4 Therapeutics. And I've got with me Andrew Hirsch, President and CEO; and Stew Fischer, Chief Scientific Officer. So, thank you both for joining me and sitting down for a conversation.
Andrew Hirsch
C4 Therapeutics, Inc. - President, CEO & Director
Great. Thanks, Brad, for having us.
Stew Fischer
C4 Therapeutics, Inc. - Chief Scientific Officer
Thanks, Brad.
Questions & Answers
Brad Canino
Stifel Financial Corp. - Analyst
So we're going to jump right into trying to cover all of the assets, which might be an impossible feat. But we're going to do our best. On the lead asset, CFT7455 or IKZF1 and IKZF3 degrader -- just open with current comments and what you can share about the status of
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot